Modified rifampin nanoparticles: Increased solubility with slow release Rate.

BACKGROUND: Recent advances in nanotechnology-based drug delivery system have been shown to improve either antibacterial efficacy or pharmacokinetics behavior.The aim of this study was to design a rifampin nanoparticle (RIF-NP) which has a high loading capacity with the slow release profile. MATERIAL AND METHODS: The designed chitosan/gelatin/lecithin (Chg/L) RIF-NPs were prepared by multilamellar vesicle. Thereafter, the particle size, zeta potential, morphology, and release rate were investigated. To optimize the loading capacity and release profiles, different concentrations of lecithin were used. RESULTS: Our results showed a correlation of lecithin concentration with size, zeta potential, and loading capacity of RIF-NPs. Increases in lecithin concentration (0.2-2.0 g) could cause a significant size reduction in NPs (250-150 nm); the amount of zeta potential (from 14 to 49 mV;P < 0.05) and loading capacity increases from 8% to 20% (P < 0.05). Designed NPs had slow drug release profile which was influenced by pH and lecithin concentration. The cumulative percentage of RIF released at pH 7.4 was approximately 93% up to 12 h. In overall, release profile was better than standard drug, even in various pH conditions (pH = 1, 3.4, and 7.4). The Chg/L-RIF NPs may be considered as a promising drug nanocarrier. CONCLUSIONS: These NPs release RIF in slow and constant rate, which effectively might eliminate the bacilli and prevent the formation of RIF-resistant bacilli.

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial.

Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment.

Breathlessness from the Perspective of the Persian Medicine.

Dyspnea is one of the most complaints in the pulmonary diseases. Shortness of breath as a subjective symptom can decrease the quality of life of patients. Although symptomatic treatment of the patients with chemical drugs is efficient in sign reduction, drugs side effect and allowing the disease to become chronic are risky for patients. Nowadays, traditional medicine is considered as an effective strategy in patients' treatment by World Health Organization. This study discusses the causes of shortness of breath from the view of Iranian traditional medicine and describes some suggestion for treatment of causes of this problem. Persian medicine prioritizes prevention of diseases by offering some strategies. In case of disease occurrence, life style modifications and herbal pharmaceutical therapy are recommended.

The effect of supplemental zinc on the height and weight percentiles of children.

BACKGROUND: Considering the high incidence of low weight and short stature among Iranian children as well as the high prevalence of both mild and moderate types of zinc deficiency, this study was conducted among patients who were referred to the Pediatric Clinic at Massih Daneshvari Hospital during 1997 - 1999. The aim of this study was to determine the effect of zinc supplementation on the children's height and weight percentiles. METHODS: Age, sex, and height and weight percentiles before and after administration of zinc were determined and recorded. The zinc supplement used in this project was in the form of a zinc sulfate solution in 0.1% and 0.5% concentrations. The dose was the upper limit of a tolerable dose, which was given in three divided doses per day. The serum zinc level was measured with the atomic absorption spectrophotometry method. The effect of age, sex, and initial serum zinc level on the percentile changes were determined. RESULTS: This study was conducted on 42 children with equal distribution of gender (21 male and 21 female patients). The mean age was 4.9 +/- 4.1 years. Means of height and weight were 101.8 +/- 23 cm and 16.5 +/- 8.1 kg, respectively. The initial serum zinc level was 85.1 +/- 31.6 microg/dL. The duration of zinc administration was 3.2 +/- 2.6 months. The subjects were followed for a minimum of one month to a maximum of 10 months. The percentage of children with weight and height percentiles below the 50th percentile was reduced from 69% to 54% (P < 0.05) and from 50% to 33% (P < 0.01), respectively. Also, it was noted that children with low serum zinc levels demonstrated greater percentile changes. CONCLUSION: It was concluded that supplemental zinc increases height and weight percentiles.